Bristol-Myers Squibb joined the urology treatment developer's investors in a round led by Yonghua Capital.
US-based urology treatment developer Taris Biomedical has secured $25m in a series B round backed by pharmaceutical firm Bristol-Myers Squibb (BMS).
Venture capital fund Yonghua Capital led the round, which also featured Flagship Pioneering, Polaris Partners, RA Capital Management and Norma Investments.
Founded in 2008, Taris Biomedical is developing non-invasive treatments for urological conditions such as bladder cancer. Its aim is to facilitate the steady release of drugs in the bladder over periods of weeks or months.
The funds will…
